Johnson & Johnson Common Stock

The company maintains sufficient liquidity to cover remaining litigation obligations, though the talc reserve has been adjusted following the dismissal of bankruptcy proceedings. (1 in progress across 1 tracked commitment)

The company plans to complete the separation of its Orthopaedics business within a specific timeframe. — target: completion of separation (+1 more commitment)

Management expects the launch of biosimilar versions of SIMPONI to reduce future sales in Europe and the U.S. — target: reduction in future sales

Management expects generic competition for OPSUMIT in the U.S. to result in a reduction in future sales. — target: reduction in future sales (+1 more commitment)

Management expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025, which will impact sales.

Profitability in the pharmaceutical segment improved significantly, with margins expanding from 35.0% to 38.6%. This was driven by lower R&D spending as a percentage of sales and the absence of large one-time acquisition charges seen in the prior year. (2 expanding across 1 engine)

The segment remains the primary revenue engine, growing to a 64.0% share of total sales. Growth was driven by Oncology (up 21.1%) and Neuroscience (up 3.2%), though partially offset by a significant decline in Stelara sales due to biosimilar competition. (5 expanding across 1 engine)

The balance sheet remains a core advantage but saw a decrease in cash and an increase in debt to fund major acquisitions. Net debt rose to $27.8 billion from $12.1 billion following the $14.5 billion Intra-Cellular acquisition. (2 shifted)

The company utilized its balance sheet strength to complete the $14.5 billion acquisition of Intra-Cellular Therapies, adding the mental health drug CAPLYTA to its portfolio. This resulted in a decrease in cash and an increase in long-term debt. (2 shifted, 1 exited)

The moat is facing a significant challenge as Stelara, a key immunology drug, experienced a 38.6% worldwide sales decline due to the entry of biosimilar competitors (lower-cost versions of biologic drugs). (3 contracting, 1 shifted)

The Cardiovascular franchise is showing significant acceleration, with operational growth jumping to 17.7% this quarter, largely driven by the acquisition of Shockwave Medical and strong adoption of Abiomed's Impella products. (5 accelerating across 5 signals, 1 leading indicator)

The Cardiovascular franchise is accelerating significantly, driven by the acquisition of Shockwave and strong performance in Electrophysiology, which grew 16.5% operationally in the first nine months. (1 accelerating, 2 new trend, 2 steady across 5 signals, 2 leading indicators)

J&J is accelerating its capacity building, with capital expenditures for property, plant, and equipment rising to over $1 billion this quarter, up from $795 million last year. (1 accelerating, 1 decelerating, 3 steady across 5 signals, 2 leading indicators)

The reported margin shows a massive one-time acceleration (from 17.4% to 62.3%) due to the reversal of a $7.0 billion talc litigation reserve. Excluding this, underlying margins are pressured by unfavorable currency and the Shockwave acquisition costs. (2 accelerating, 3 reversing across 5 signals)

A major growth hurdle is the loss of patent protection for STELARA, which caused a significant 60% drop in sales for that specific drug this quarter. — STELARA Sales Decline: 59.7% decline YoY

The risk is stable as the timeline for generic entry remains the second half of 2026. Management explicitly warns this will likely result in a reduction in future sales. (1 stable)

The company is spending heavily on restructuring its Surgery and Orthopaedics businesses to simplify operations. While intended to save money later, these programs are currently costing hundreds of millions in exit costs and asset write-downs. [EXECUTION]

The risk is stable as litigation remains ongoing, but the company notes that Medicare Part D redesign is already negatively impacting sales of several key products like IMBRUVICA and XARELTO. (1 stable)

The risk is intensifying as biosimilar competition is now a primary driver of revenue decline in the Immunology segment, with a 42.7% drop in STELARA sales this quarter. (2 intensifying)

The risk is intensifying as the company initiated a new restructuring program for the Surgery franchise in 2025 with estimated total costs of $0.9 - $1.0 billion. (1 intensifying)